advertisement
Abstract #10124 Published in IGR 6-1
Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures
Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda FJournal of Glaucoma 2004; 13: 149-157
BACKGROUND: To compare the intraocular pressure (IOP) lowering effect, tolerability, and patient-reported measures of the dorzolamide/timolol fixed combination and the concomitant administration of brimonidine and timolol after three months. METHODS: Four hundred and ninety-two patients with ocular hypertension, primary open-angle glaucoma, exfoliative glaucoma, or pigmentary glaucoma participated in this randomized, observer-masked, multicenter study. Following three weeks of timolol monotherapy, patients with a peak IOP of ≥ 2 mmHg were randomized to receive either fixed combination dorzolamide/timolol twice daily or concomitant brimonidine plus timolol twice daily for three months. The IOP-lowering effects at peak and trough, tolerability, and patient-reported convenience and satisfaction were measured at one and three months. RESULTS: At the three-month peak, the dorzolamide/timolol group had an adjusted mean (SE) change from baseline IOP of -4.30 (0.24) mmHg versus -5.27 (0.23) the brimonidine-plus-timolol group, with a treatment difference of 0.97 mmHg (95% CI: 0.40, 1.53). At the three-month trough time point and both one-month time points, the 95% CIs of the treatment differences were within the prespecified comparability boundary of ± 1.5 mmHg. The incidence of drug-related adverse experiences was similar between treatment groups. Patient-reported assessments of convenience and satisfaction showed no statistically significant differences between treatment groups. CONCLUSIONS: The IOP-lowering effect of the dorzolamide/timolol fixed combination and concomitant brimonidine plus timolol were comparable at three of the four time points measured. Patient-reported measures and the incidence of adverse experiences in both treatment groups were similar.
Dr. A.M. Solish, Southern California Glaucoma Consultants, Pasadena, CA, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
